Literature DB >> 17482301

The role of radiotherapy in lung cancer: where is the evidence?

Jacek Jassem1.   

Abstract

Radiotherapy is one of the main treatment modalities in lung cancer, contributing to both its cure and palliation. Thoracic irradiation has traditionally been considered the mainstay of treatment in inoperable stage III non-small cell lung cancer. However, despite technical developments and the addition of chemotherapy, the curative potential of radiotherapy in this subset of patients is disappointingly poor. The role of radiotherapy as an adjunct to pulmonary resection (preoperative and postoperative) is questionable, but well-designed and executed phase III studies are lacking. An important application of radiotherapy is palliation of tumor-related symptoms in the chest and in metastatic sites, such as bones and brain. In small cell lung cancer, routine applications of radiotherapy include chest radiotherapy in limited disease and prophylactic cranial irradiation in complete responders to chemotherapy, each increasing survival by about 5%.

Entities:  

Mesh:

Year:  2007        PMID: 17482301     DOI: 10.1016/j.radonc.2007.04.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Long non-coding RNA transcribed from pseudogene PPIAP43 is associated with radiation sensitivity of small cell lung cancer cells.

Authors:  Shilong Wang; Jinming Yu
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

2.  CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?

Authors:  D Calvo Temprano; E Esteban; P Jiménez Fonseca; B Fernández-Mariño
Journal:  Clin Transl Oncol       Date:  2016-04-18       Impact factor: 3.405

3.  Changes in functional lung regions during the course of radiation therapy and their potential impact on lung dosimetry for non-small cell lung cancer.

Authors:  Xue Meng; Kirk Frey; Martha Matuszak; Stanton Paul; Randall Ten Haken; Jinming Yu; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

4.  AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.

Authors:  Pavithra Raghavan; Vasu Tumati; Lan Yu; Norman Chan; Nozomi Tomimatsu; Sandeep Burma; Robert G Bristow; Debabrata Saha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-12       Impact factor: 7.038

5.  Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?

Authors:  Malene Støchkel Frank; Dorte Schou Nørøxe; Lotte Nygård; Gitte Fredberg Persson
Journal:  BMC Palliat Care       Date:  2018-01-05       Impact factor: 3.234

6.  Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways.

Authors:  Pierfrancesco Franco; Gianmauro Numico; Fernanda Migliaccio; Paola Catuzzo; Domenico Cante; Paola Ceroni; Piera Sciacero; Pierpaolo Carassai; Paolo Canzi; Maria Rosa La Porta; Giuseppe Girelli; Valeria Casanova Borca; Massimo Pasquino; Santi Tofani; Franca Ozzello; Umberto Ricardi
Journal:  Radiat Oncol       Date:  2012-02-15       Impact factor: 3.481

7.  Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy.

Authors:  Marika Crohns; Seppo Saarelainen; Hannu Kankaanranta; Eeva Moilanen; Hannu Alho; Pirkko Kellokumpu-Lehtinen
Journal:  Free Radic Res       Date:  2009-07

8.  Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response.

Authors:  Anne Hansen Ree
Journal:  Radiat Oncol       Date:  2008-05-19       Impact factor: 3.481

9.  Quantitative analysis of tumor shrinkage due to chemotherapy and its implication for radiation treatment planning in limited-stage small-cell lung cancer.

Authors:  Bing Xia; Jia-Zhou Wang; Qi Liu; Jing-Yi Cheng; Zheng-Fei Zhu; Xiao-Long Fu
Journal:  Radiat Oncol       Date:  2013-09-16       Impact factor: 3.481

10.  Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial.

Authors:  Zhengfei Zhu; Wei Liu; Michael Gillin; Daniel R Gomez; Ritsuko Komaki; James D Cox; Radhe Mohan; Joe Y Chang
Journal:  Radiat Oncol       Date:  2014-05-06       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.